Cambridge, MA, United States of America

Katarina Blagovic

This inventor holds 3 USPTO granted patents and 6 published patent applications and 1 EPO patent. Top assignees: Sqz Biotechnologies Company, Stemcell Technologies Canada Inc.. Active years: 2023-2026.

USPTO Granted Patents = 3 

% Patents Active = 66.7

 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2023-2026

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Katarina Blagovic

Introduction

Katarina Blagovic is an accomplished inventor based in Cambridge, MA. She has made significant contributions to the field of biotechnology, particularly in the area of immune response modulation. Her work focuses on the delivery of biomolecules to peripheral blood mononuclear cells (PBMCs), which has important implications for therapeutic applications.

Latest Patents

Katarina holds a patent for the "Delivery of biomolecules to PBMCs to modify an immune response." This patent outlines methods for manufacturing PBMCs that are conditioned to modulate an immune response in individuals. The application details the use of adjuvants to enhance the effectiveness of these PBMCs, showcasing her innovative approach to immunotherapy.

Career Highlights

Katarina is currently associated with Sqz Biotechnologies Company, where she continues to advance her research and development efforts. Her work at Sqz Biotechnologies reflects her commitment to improving health outcomes through innovative biotechnological solutions.

Collaborations

Katarina collaborates with notable colleagues, including Armon R Sharei and Howard Bernstein. These partnerships enhance her research capabilities and contribute to the advancement of their shared goals in biotechnology.

Conclusion

Katarina Blagovic is a pioneering inventor whose work in the delivery of biomolecules to PBMCs is paving the way for new therapeutic strategies. Her contributions to biotechnology are significant and continue to impact the field positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…